Ian Sanne to Viral Load
This is a "connection" page, showing publications Ian Sanne has written about Viral Load.
Connection Strength
1,995
-
Evaluation of GeneXpert and advanced biological laboratories UltraGene HCV diagnostic detection and performance against Roche real time PCR in Myanmar. J Clin Virol. 2024 04; 171:105653.
Score: 0,169
-
Treatment outcomes among HIV-positive orphaned and non-orphaned children on antiretroviral therapy in Johannesburg, South Africa. S Afr Med J. 2019 Aug 28; 109(9):679-685.
Score: 0,124
-
Varying intervals of antiretroviral medication dispensing to improve outcomes for HIV patients (The INTERVAL Study): study protocol for a randomized controlled trial. Trials. 2017 Oct 13; 18(1):476.
Score: 0,109
-
Cohort profile: the Right to Care Clinical HIV Cohort, South Africa. BMJ Open. 2017 06 10; 7(6):e015620.
Score: 0,107
-
Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. J Leukoc Biol. 2016 07; 100(1):223-31.
Score: 0,096
-
CD4 criteria improves the sensitivity of a clinical algorithm developed to identify viral failure in HIV-positive patients on antiretroviral therapy. J Int AIDS Soc. 2014; 17:19139.
Score: 0,088
-
The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa. PLoS One. 2013; 8(8):e71719.
Score: 0,082
-
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93.
Score: 0,080
-
The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting. Trop Med Int Health. 2013 May; 18(5):619-31.
Score: 0,079
-
Treatment outcomes after 7 years of public-sector HIV treatment. AIDS. 2012 Sep 10; 26(14):1823-8.
Score: 0,077
-
Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol. 2013 Apr; 42(2):430-9.
Score: 0,074
-
Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment. AIDS. 2011 Oct 23; 25(16):2027-36.
Score: 0,072
-
Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011 Apr; 56(4):349-55.
Score: 0,069
-
High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):500-6.
Score: 0,065
-
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003 Jan 01; 32(1):18-29.
Score: 0,039
-
Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts. Sci Rep. 2022 07 26; 12(1):12715.
Score: 0,038
-
Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set. J Viral Hepat. 2022 06; 29(6):474-486.
Score: 0,037
-
Deciding when to institute terminal palliative care for AIDS patients--an evidence-based approach. S Afr Med J. 2001 Jul; 91(7):559-60.
Score: 0,035
-
Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem? Int J Infect Dis. 2001; 5(1):43-8.
Score: 0,034
-
Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial. J Acquir Immune Defic Syndr. 2020 11 01; 85(3):280-291.
Score: 0,034
-
Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. AIDS. 2020 04 01; 34(5):681-686.
Score: 0,032
-
HIV incidence, pregnancy, and implementation outcomes from the Sakh'umndeni safer conception project in South Africa: a prospective cohort study. Lancet HIV. 2019 07; 6(7):e438-e446.
Score: 0,031
-
Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa. AIDS Res Ther. 2018 04 10; 15(1):10.
Score: 0,028
-
Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa. Trop Med Int Health. 2017 02; 22(2):221-231.
Score: 0,026
-
HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. J Antimicrob Chemother. 2017 01; 72(1):210-219.
Score: 0,025
-
Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. PLoS One. 2016; 11(8):e0161469.
Score: 0,025
-
Comparative Evaluation of the Diagnostic Performance of the Prototype Cepheid GeneXpert Ebola Assay. J Clin Microbiol. 2016 Feb; 54(2):359-67.
Score: 0,024
-
Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa. Int J Infect Dis. 2014 Jun; 23:56-62.
Score: 0,021
-
Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health. 2014 May; 19(5):490-8.
Score: 0,021
-
Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial. PLoS One. 2013; 8(12):e74900.
Score: 0,021
-
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013 Nov 15; 208(10):1624-8.
Score: 0,020
-
Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS. 2013 Feb 20; 27(4):645-50.
Score: 0,020
-
Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals. AIDS. 2012 Jul 17; 26(11):1355-62.
Score: 0,019
-
Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clin Infect Dis. 2012 Sep; 55(5):737-45.
Score: 0,019
-
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
Score: 0,018
-
Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa. J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb; 11(1):57-65.
Score: 0,018
-
The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc. 2011 May 15; 14:24.
Score: 0,017
-
Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African women. J Int AIDS Soc. 2010 Sep 07; 13:33.
Score: 0,017
-
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 2010 Aug 24; 24(13):2041-50.
Score: 0,017
-
Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 2010 Apr 01; 50(7):1041-52.
Score: 0,016
-
Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis. 2009 Jul; 13(4):488-92.
Score: 0,015
-
CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S131-40.
Score: 0,014
-
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis. 2004 Jul 15; 190(2):280-4.
Score: 0,011
-
T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment. AIDS. 2003 May 23; 17(8):1145-9.
Score: 0,010